Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Inclusion Criteria:

   - Patients must have persistent, metastatic, or recurrent platinum resistant or
   refractory ovarian or primary peritoneal cancer.

   - No restriction on previous treatment regimens, but patients must be at least 2 weeks
   out from last chemotherapy or investigational agent.

   - Patients must be >= 18.

   - Patients must have a life expectancy of at least 6 months.

   - Patients must have KPS >= 60.

   - Patients must have acceptable organ and marrow function as defined below (within 2
   weeks prior to radiotherapy):

      - leukocytes >=3,000/uL

      - absolute neutrophil count >=1,500uL

      - platelets >=100,000/uL

      - total bilirubin within 1.5X normal institutional limits

      - AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal

      - creatinine within normal institutional limits OR

      - creatinine clearance >=60 mL/min/1.73 m^2 for patients with creatinine levels
      above institutional normal

   - Patients must be willing to undergo a pre- and post-treatment FDG-PET/CT.

   - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

   - Patients should not have received radiation overlapping with the proposed treatment
   field.

   - Patients cannot be receiving chemotherapy or other investigation agents from two weeks
   prior to radiation through undergoing their post-therapy FDG-PET/CT

   - Patients cannot be pregnant or nursing.

   - Patients cannot have disease >= 8cm or greater than 3 regions of disease.

   - Patients cannot have concurrent malignancy other than non-melanoma skin cancer,
   non-invasive bladder cancer, or carcinoma in situ of the cervix.